Assessment of imatinib as first-line treatment of chronic myeloid leukemia: 10-year survival results of the randomized CML study IV and impact of non-CML determinants

Assessment of imatinib as first-line treatment of chronic myeloid leukemia: 10-year survival results of the randomized CML study IV and impact of non-CML determinants Leukemia advance online publication, September 12 2017. doi:10.1038/leu.2017.253 Authors: R Hehlmann, M Lauseker, S Saußele, M Pfirrmann, S Krause, H J Kolb, A Neubauer, D K Hossfeld, C Nerl, A Gratwohl, G M Baerlocher, D Heim, T H Brümmendorf, A Fabarius, C Haferlach, B Schlegelberger, M C Müller, S Jeromin, U Proetel, K Kohlbrenner, A Voskanyan, S Rinaldetti, W Seifarth, B Spieß, L Balleisen, M C Goebeler, M Hänel, A Ho, J Dengler, C Falge, L Kanz, S Kremers, A Burchert, M Kneba, F Stegelmann, C A Köhne, H W Lindemann, C F Waller, M Pfreundschuh, K Spiekermann, W E Berdel, L Müller, M Edinger, J Mayer, D W Beelen, M Bentz, H Link, B Hertenstein, R Fuchs, M Wernli, F Schlegel, R Schlag, M de Wit, L Trümper, H Hebart, M Hahn, J Thomalla, C Scheid, P Schafhausen, W Verbeek, M J Eckart, W Gassmann, A Pezzutto, M Schenk, P Brossart, T Geer, S Bildat, E Schäfer, A Hochhaus & J Hasford
Source: Leukemia - Category: Hematology Authors: Source Type: research